Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feromaks is an oral iron supplement developed and marketed by Shayana Farm, primarily available in a syrup formulation. The active ingredient is iron(III) hydroxide polymaltose complex (IPC), a non-ionic iron preparation where the polynuclear iron(III) hydroxide core is surrounded by non-covalently bound polymaltose molecules. This complex is designed to mimic the physiological storage form of iron (ferritin), allowing for controlled iron release and absorption via active transport mechanisms in the small intestine. This pharmacokinetic profile significantly reduces the risk of gastrointestinal irritation and oxidative damage often associated with traditional ferrous salts. Feromaks is indicated for the treatment of latent iron deficiency and iron deficiency anemia, as well as for the prevention of iron deficiency during pregnancy and lactation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iron(III) hydroxide polymaltose complex.